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Background. A wealth of evidence obtained using mouse models indicates that CD4+CD25+FOXP3+ regulatory T cells (Treg)
maintain peripheral tolerance to self-antigens and also inhibit anti-tumor immune responses. To date there is limited
information about CD4+ T cell responses in patients with colorectal cancer (CRC). We set out to measure T cell responses to
a tumor-associated antigen and examine whether Treg impinge on those anti-tumor immune responses in CRC patients.
Methodology and Principal Findings. Treg were identified and characterized as CD4+CD25+FOXP3+ using flow cytometry. An
increased frequency of Treg was demonstrated in both peripheral blood and mesenteric lymph nodes of patients with
colorectal cancer (CRC) compared with either healthy controls or patients with inflammatory bowel disease (IBD). Depletion of
Treg from peripheral blood mononuclear cells (PBMC) of CRC patients unmasked CD4+ T cell responses, as observed by IFNc
release, to the tumor associated antigen 5T4, whereas no effect was observed in a healthy age-matched control group.
Conclusions/Significance. Collectively, these data demonstrate that Treg capable of inhibiting tumor associated antigen-
specific immune responses are enriched in patients with CRC. These results support a rationale for manipulating Treg to
enhance cancer immunotherapy.
Citation: Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, et al (2006) CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune
Responses in Patients with Colorectal Cancer. PLoS ONE 1(1): e129. doi:10.1371/journal.pone.0000129
INTRODUCTION
Colorectal cancer (CRC) is the fourth most commonly diagnosed
malignant disease with an estimated 1 million new cases and over
500 000 deaths each year worldwide [1]. The current manage-
ment of patients with CRC revolves around excision of the
primary tumor and the local lymph nodes and the selective use of
5-fluorouracil (5FU; inhibits thymidylate synthase) based chemo-
therapy [2]. Recent advances in preoperative imaging, surgical
technique and the use of neo-adjuvant chemotherapy have
improved outcomes, but colorectal cancer remains the second
leading cause of death from cancer in Western countries with 40–
50% of patients who undergo a potentially curative operation,
undergoing relapse or death from metastatic disease.
Clinico-pathological staging of the disease strongly correlates
with prognosis. Interestingly, improved clinical outcome is also
associated with the presence of tumor-infiltrating lymphocytes
(TILs), particularly if the lymphocytes invade the glandular
elements of the tumor [3,4]. This suggests that anti-tumor immune
responses can impinge on the growth of the primary tumor, and
may have an important role in controlling metastatic disease.
Indirect evidence for the importance of the immune response in
cancer patients is the epidemiological association in some
populations between an increased incidence of tumors and
immunosuppression post organ transplantation [5].
Much interest has recently arisen in the role of a naturally
occurring population of CD4+CD25+ regulatory T cells (Treg),
characterized by expression of the forked-head transcription factor
FOXP3, and increased levels of the surface markers CD45RO,
CTLA-4, and GITR [6,7,8]. Treg have been shown to control
self-antigen specific responses in the periphery, and hence may
play a role in controlling anti-tumor immune responses. Several
groups including our own, have demonstrated that depletion of
Treg promotes the generation of anti-tumor immune responses
and tumor rejection in murine models (reviewed in [9]). There is
evidence to suggest that these protective responses target both
tumor-specific antigens as well as shared tumor antigens [10,11].
More recently, several studies have observed an increased
frequency of CD4+CD25+ T cells in the peripheral blood of
patients with various types of cancer, although the majority of
these studies did not confirm that these were Treg by staining for
FOXP3 (reviewed in [9]). The presence of FOXP3+ Treg within
the TILs of ovarian cancer has, however, been identified as an
independent risk factor for poorer prognosis. Furthermore, after
purification from tumor ascites, these Treg were shown to suppress
Her2-specific T cell responses in vitro [12].
The human onco-fetal antigen, 5T4, is a 72kDa leucine-rich
membrane glycoprotein which is expressed at high levels on the
placenta and also on a wide range of human carcinomas including
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colorectal, gastric, renal and ovarian but rarely on normal tissues
[13,14,15,16,17,18]. In this study we tested the hypothesis that
Treg develop in CRC patients that suppress 5T4-specific immune
responses. Samples from patients with CRC or IBD, and healthy
controls were examined to address three questions: is the
frequency of Treg (CD25hiCD4+FOXP3+ T cells) increased in
blood or lymph nodes from patients with CRC; can anti-tumor T
cell responses to 5T4 be identified in CRC patients; and do Treg
impinge on these anti-tumor immune responses?
METHODS
Sample groups
CRC patients were identified from multi-disciplinary team meet-
ings with the first presentation of an adenocarcinoma and no
reported distant metastases on cross sectional imaging (TNM stage
I–III; Duke’s stage A–C). IBD patients (ulcerative colitis or Crohn’s
disease) attending clinic or undergoing elective surgical resection
were recruited to the study. Local ethical committee approval was
granted for the study by the Bro Taf Local Research Ethics
Committee.
Antigens
Purified protein derivative (PPD) (Statens Serum Institut, Den-
mark), hemaglutinin (HA) was a kind gift from Dr John Skehel
(NIMR, Mill Hill), 5T4 was produced as described previously [19]
(Oxford Biomedica). All antigens were used at a final concentra-
tion of 1 mg/ml.
Purification of lymphocytes
30–50 ml of blood was drawn from patients or controls and
heparinized (10 U/ml). PBMCs were extracted by centrifugation
over Lymphoprep (Axis-Shield, Oslo, Norway). The cells were
washed twice in RPMI before further use. Lymph nodes were
dissected from fresh specimens within 30 minutes of surgery,
washed in RPMI, mashed through a sterile cell strainer and
collected by centrifugation.
Flow cytometric analysis of lymphocytes from blood
and lymph nodes
Samples were stained with fluorescently-labeled antibodies to CD4
(clone RPA-T4), CD25 (clone M-A251), CD45RO (clone UCHL1)
and CTLA4 (clone BNI3) (BD Pharmingen), CD4 (clone S3.5)
(Caltag) and CD25 (clone 4E3) (Miltenyi Biotec). All staining was
performed in phosphate buffered saline (PBS), 2.5% FCS, 5 mM
EDTA and intracellular staining was performed using the cytofix,
cytoperm kit (BD Pharmingen). FOXP3 staining was performed
using the FITC anti-human FOXP3 staining kit (clone PCH101)
(71-5776 eBioscience). Lymphocytes were gated on forward and
side scatter profiles. All flow cytometry was performed on a BD
FacsCalibur and analyzed using the Summit v3.1 analysis program
(build 839 Dakocytomation, Fort Collins, Colorado).
CD4+CD25hi add-back experiments
Purified PBMC were enriched for CD4+ cells and then separated
into CD4+CD25hi and CD4+CD252 fractions using magnetic
beads (Miltenyi CD4+CD25+ regulatory isolation kit). Flow
cytometry of each fraction showed that the stringency of CD25+
cell selection by the Miltenyi CD4+CD25+ regulatory isolation kit
and Miltenyi anti-CD25 beads was comparable. A proliferation
assay was set up using 2x104 CD4+CD252 cells, activated with
0.5 mg/ml plate-bound anti-CD3 (clone OKT3) (eBioscience) and
1 mg/ml soluble anti-CD28 (clone 28.2) (BD Pharmingen)
antibodies in RPMI 1640 supplemented with 10% heat-treated
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-
glutamine and 1 mM sodium pyruvate. CD4+CD252 cells were
activated alone or in the presence of CD4+CD25hi at cells varying
ratios of 1:1, 1:0.1, 1:0.01 and 1:0.001 CD4+CD252:CD4+CD25hi
cells. Proliferation was measured on day 3 by the addition of
0.037 MBq/well (1 mCI) of [methyl-3H]-thymidine (Amersham
Biosciences) for the final 18 hours of culture. Cells were harvested
onto printed filtermat A filters (Wallac, Turku, Finland supplier
Perkin Elmer) using a TomTek cell harvester. Once filters were
dry, meltilex A melt-on scintillator sheets (Wallac) were added and
filters were read using a Trilux 1450 microbeta liquid scintillation
and luminescence counter (Wallac).
IFN-c ELISPOT assays
Antibodies were obtained from Mabtech (Natka, Sweden) and the
ELISPOT was developed using the alkaline phosphatase substrate
kit from Bio-Rad (Hercules, California). The effect of Treg
depletion on antigen-specific IFN-c production was assessed in
parallel assays. CD25hi cells were depleted using magnetic
separation with MACs CD25 microbeads (Miltenyi Biotec,
Germany). Briefly, 1.56107 PBMC were incubated with 15 ml of
anti-CD25 coated beads in total reaction volume of 150 ml of
buffer (16PBS, 0.5% BSA, 5 mM EDTA) at 4uC for 15 min.
Excess beads were washed off and the PBMC were run down an
MS column. The column was washed with 361 ml washes in
buffer. The efficacy of depletion was confirmed by flow cytometry.
Assays were set up using either 3.56105 undepleted or CD25hi-
depleted cells in RPMI 1640 supplemented with 5% heat-treated
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-
glutamine and 1 mM sodium pyruvate per well of a polymer-
backed 96-well filtration plate (MAIP-S-4510) (Millipore, Mos-
lheim, France) in a total reaction volume of 100 ml/well. The
concentrations of antibodies used and washing steps were
according to the manufacturer’s instructions, all antibody incuba-
tions were with 50 ml/well. The method has been previously
described [20]. PPD, HA and 5T4 were tested in duplicate wells,
having been added to a final concentration of 1 mg/ml, and
compared with control wells with no protein. The plate was
incubated at 37uC, 5% CO2 for 18 h. Activated T cells were
enumerated at the single-cell level by counting the number of spots
per well using an automated ELISPOT reader (Cadama).
Responders were identified as having at least 5 spot-forming cells
(sfc) per 106 PBMC, after subtraction of the background, and an
increase of at least 50% above background.
Statistical analysis
Flow cytometric data was analyzed using the unpaired student’s t-
test (GraphPad Prism version 2.0 (GraphPad software). The
proportion of cancer patients and healthy controls mounting
a response to 5T4 was compared using a closed form method for
comparing differences and calculating confidence intervals [21].
RESULTS
Defining the human Treg population
Using the strict gating parameters reported recently [8], Treg were
identified as CD4 positive cells with brighter CD25 staining than
that of the CD4-negative population (Fig 1a). The frequency of
Treg was calculated as the percentage of CD4+CD25hi cells in the
CD4+ population, and was in the range of 0.09–1.44% of CD4+
cells in PBMC of healthy age-matched controls. In keeping with
previous reports, the vast majority of CD4+CD25hi cells were
CTLA4-positive and expressed CD45RO (.97%) [6,7,8]. The
Anti-Tumor Immunity
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CD25hi population was further analyzed by the expression of
FOXP3. As shown in Figure 1b, over 95% of CD4+CD25hi cells
expressed FOXP3, compared with approximately 30% of
CD4+CD25int cells. This pattern of staining was the same for
both healthy controls and CRC patients. FOXP3 expression was
negligible in CD4+CD252 cells (Figure 1b).
To confirm the regulatory phenotype of this population of
CD4+CD25hi cells, their ability to suppress the activation of
CD4+CD252 cells was assessed using a co-culture in vitro pro-
liferation assay. CD4+CD252 and CD4+CD25hi cells were separat-
ed from PBMC, as described in methods. The addition of
CD4+CD25hi cells to polyclonally stimulated CD4+ T cells clearly
suppressed the proliferation of CD4+CD252 T cells and, as reported
by others, this suppression was dose-dependent [8,22,23] (Figure 1c).
CRC patients have increased numbers of Treg in
peripheral blood
The Treg were phenotypically defined as outlined above. Figure 2a
shows the frequencies of Treg in the PBMCs of CRC patients
(n = 12, age range 58–80 years) compared with age-matched
healthy controls (n = 11, age range 48–93 years) and patients with
inflammatory bowel disease (n = 22, age range 19–80 years). In all
groups, the frequency of Treg was less than 2% of CD4+ T cells.
However, the mean frequency in CRC patients (1.13%) was
significantly increased compared with the control groups (IBD
patients 0.56%, healthy controls 0.46%). There was no significant
difference in the frequency of Treg in healthy controls and IBD
patients.
CRC patients have increased numbers of Treg in
mesenteric lymph nodes
Obtaining control lymph nodes from subjects with no abdominal
disease was not possible. IBD patients offer a colonic disease
control group to the CRC patients, the latter also often
demonstrating areas of inflammation around the tumor. Further-
more, the results from PBMCs did not demonstrate a significant
alteration in the frequencies of Treg in patients with IBD
compared with healthy controls. Hence, we considered it reason-
able to use mesenteric lymph nodes obtained from IBD patients
undergoing surgery as a control group in which to examine Treg
in secondary lymphoid tissue.
Fresh lymph nodes were obtained from the surgically resected
specimens and prepared as outlined in methods. The frequencies of
Treg in mesenteric lymph nodes obtained from CRC patients
(n= 8), and IBD patients (n= 7) were compared (Figure 2b). CRC
patients again showed a significant increase in the frequency of
Treg, reflecting the increase already described in peripheral blood.
The lymph node-derived CD25hi Treg had the same phenotype to
those found in blood (data not shown). No difference was observed
in the overall proportion of CD4+ or CD8+ T cells (data not shown).
Figure 1. Characterization of the human Treg population. (A) CD4+CD252, CD4+CD25int and CD4+CD25hi cells were identified as shown.
CD4+CD25hi cells are those where CD25 expression was higher than that on the CD42 population. (B) FOXP3 expression within each population was
assessed by intracellular staining. (C) Freshly isolated CD4+CD252 T cells (26104 cells/well) were cultured alone (CD25-/low) or with CD4+CD25hi T
cells at various ratios, and stimulated with plate-bound anti-CD3 and soluble anti-CD28. Proliferation was assessed by (3H)-thymidine incorporation.
The results represent the average of triplicate wells with standard deviation, from a representative assay.
doi:10.1371/journal.pone.0000129.g001
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Patients with non-metastatic CRC demonstrate
vigorous CD4+ T cell responses to recall antigens
PBMCs were purified from CRC patients (n = 14) prior to surgery
and the specific CD4+ T cell response to the control recall antigens
PPD and HA measured by IFN-c release. These results were
compared with healthy age-matched controls (n = 11) (Figure 3).
CD4 and CD8 depletion experiments confirmed that these were
CD4+ T cell responses (data not shown). There was no evidence
that the patients were immunosuppressed; all subjects responded
to at least one antigen. Cell proliferation was also assessed in
parallel experiments as a measure of T cell activation, and again
no evidence of immunosuppression was found pre-operatively
(data not shown).
Treg have a marked effect on anti-tumor immune
responses in the blood of patients with CRC
A series of assays were performed on CRC patients (n= 14) and age-
matched controls (n= 11) to determine whether removal of CD25hi
cells altered the immune response to recall antigens and the tumor-
associated antigen 5T4. We optimized an isolation system designed
specifically to deplete only the CD25hi cells from our samples as
outlined in methods (Figure 4a). Freshly-isolated PBMCs were used
in ex vivo IFN-c ELISPOT assays as outlined above to determine
responses to the recall antigens and the tumor antigen 5T4, before
and after depletion of Treg. On the whole, depletion of Treg
uncovered some responses to recall antigens in CRC patients and
controls (Figure 4b). However, in the case of the tumor associated
antigen 5T4, there was a striking difference between controls and
CRC patients. A 5T4-specific ex vivo response was found in 1/11 of
the healthy controls and depletion of Treg enhanced this response.
Whilst depletion of Treg augmented the 5T4-specific response in 1/
14 of the CRC patients, depletion of this population led to the
unmasking of a 5T4 response in 5/14 of the patients tested (95%
Confidence Interval for paired differences is 20.83 to 20.22
revealing a significant difference in 5T4 responses between CRC
patients and healthy controls). These data suggest that Treg are
suppressing anti-5T4 immune responses specifically in patients with
colorectal cancer. These six patients who demonstrated enhanced
5T4 responses had similar Treg frequencies in peripheral blood
(range 0.82–2.35% mean 1.14%) to the frequencies measured in the
entire CRC population (mean 1.13%). While IFN-c-release,
measured directly ex vivo, enabled anti-5T4 responses to be detected,
we did not find vigorous proliferative responses to 5T4 in either
CRC patients or controls. However, with several rounds of re-
stimulation and the addition of IL-2, we have grown out HLA-DR-
restricted 5T4-specific lines (data not shown).
DISCUSSION
We compared the frequency of carefully defined
CD4+CD25+FOXP3+ regulatory T cells (Treg) in CRC patients
with healthy age-matched controls and IBD patients. CRC
Figure 2. CRC patients have increased numbers of Treg cells. (A) Freshly isolated PBMC from 12 CRC patients, 11 healthy age-matched controls and
22 IBD patients were stained with antibodies to CD4 and CD25. Using the gating strategy outlined in Figure 1, Treg were enumerated. (B) Mesenteric
lymph node samples (LN) were collected from surgical specimens of 8 CRC and 7 IBD patients and stained and gated as above. The data show the
percentage of CD4+ cells that were CD25hi in each sample. Each symbol represents one patient. The p values were calculated using an unpaired
student’s t-test.
doi:10.1371/journal.pone.0000129.g002
Figure 3. CRC patients are able to mount CD4+ T cell responses to the
recall antigens PPD and HA. Whole PBMC from 11 age-matched
controls and 14 CRC patients were assessed for responses to the
antigens PPD and HA, measured by IFN-c ELISPOT. Purified PBMC were
added at 3.56105 cells/well, and incubated for 18 hours in the presence
of either 1 mg/ml PPD, 1 mg/ml HA or with no antigen. Wells were set
up in duplicate. Fewer than 5 spot forming cells/106 PBMC was
considered negative.
doi:10.1371/journal.pone.0000129.g003
Anti-Tumor Immunity
PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e129
patients have an increased frequency of Treg and there is evidence
that these Treg target anti-tumor immune responses.
We assessed whether enhanced numbers of Treg in CRC
patients correlated with general immunosuppression. A combina-
tion of IFN-c ELISPOT assays and proliferation assays to monitor
responses to the recall antigens PPD and HA, demonstrated
equally robust responses in CRC patients and healthy controls,
indicating that immune responses to non-tumor antigens are
unimpaired in CRC patients.
The pattern of immune reactivity was strikingly different
between CRC patients and healthy controls when immune
responses to the tumor-associated onco-fetal antigen, 5T4, were
Figure 4. Depletion of Treg unmasks anti-tumor CD4+ T cell responses in CRC patients but not healthy controls. (A) PBMC were purified and two
samples prepared: whole PBMC and PBMC depleted of CD25hi cells. (B) Whole PBMC and CD25hi-depleted PBMC from 11 age-matched controls (open
bars) and 14 CRC patients (solid bars) were set up in parallel in an IFN-c ELISPOT assay (3.56105 cells/well) with PPD (top graph), HA (middle graph) or
5T4 (lower graph). The number of responders is shown for each antigen. In each case, the percentage on the left is the frequency of responders that
increased after Treg depletion (Increase), the percentage in the middle is the frequency of non-responders that had a response after depletion (New
Response) and on the right the frequency of responders that showed a decrease or no change in response after Treg depletion (Decrease/NC). The
95% Confidence Interval for paired differences of proportions between patients and controls is 20.83 to 20.22 revealing a significant difference for
5T4 responses. (C) The 6 CRC patients with responses to 5T4 are shown in more detail. The bars represent the spot-forming cells/106 PBMC after
subtraction of background spots, whole PBMC (light grey) and CD25hi-depleted PBMC (dark grey). Responses were observed only in CD25hi-depleted
PBMC of patients 1–5, whilst a response was observed in both PBMC populations from patient 6. In all assays, wells were set up in duplicate.
doi:10.1371/journal.pone.0000129.g004
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compared. 5T4-specific responses were observed in a proportion
of healthy controls, but these responses were largely unaltered by
Treg depletion. In contrast, a 5T4-specific response was detected
in more than a third of the CRC patients only after removal of
Treg, suggesting that the Treg in CRC patients suppress the
tumor-specific immune response. This group of CRC patients who
demonstrated anti-5T4 responses after Treg depletion appeared to
have similar Treg frequencies compared to the overall CRC
group, although larger studies will be required to confirm this.
Since 5T4-responses were not unmasked by Treg depletion in
healthy controls, these data also indicate that Treg cells capable of
suppressing 5T4-specific responses develop in response to the
tumor. The precise mechanism through which this occurs is
unclear at present, but it is possible that the cytokine milieu within
the tumor promotes the generation of Treg recognizing tumor-
associated antigens. Recent reports indicate a role for TGFb in the
expansion of Treg [24,25]. In a rodent tumor model it has been
shown that only dendritic cells (DCs) from tumor-bearing but not
tumor-free animals promote proliferation of Treg. Interestingly
DCs from tumor-free animals could expand Treg, but only if pre-
incubated with tumor cell supernatants. These effects could be
inhibited in vitro using anti-TGFb antibodies [26]. Collectively,
these data suggest that Treg require both a tumor antigen-specific
stimulation and cytokines, such as TGFb in order to proliferate
and suppress anti-tumor immune responses.
5T4 is an attractive candidate for tumor vaccines as it is
expressed in many epithelial tumors. However, this study suggests
that Treg recognize the antigen and possibly play a role in
suppressing anti-tumor responses, presumably to the detriment of
the individual. Two other studies have demonstrated that Treg
recognize tumor antigens (LAGE-1 and ARTC-1) in subjects with
melanoma [27,28]. It is important to ensure that vaccine strategies
using tumor-associated antigens do not boost the regulatory arm of
the immune system thereby inhibiting potential anti-tumor
immunity. One approach may be to deplete Treg before
vaccination, as recently demonstrated for renal cell carcinoma
[29]. It will be of great interest therefore to determine in future
studies whether such a strategy will result in measurable clinical
responses in CRC patients.
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